Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 19/20 | 0.67 |
| ▸ | RXRB | P28702 | 5/20 | 0.67 |
| ▸ | RXRG | P48443 | 5/20 | 0.67 |
| ▸ | RARA | P10276 | 4/20 | 0.67 |
| ▸ | RARB | P10826 | 4/20 | 0.67 |
| ▸ | RARG | P13631 | 4/20 | 0.67 |
| ▸ | HNF4A | P41235 | 6/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL728016 | 1.00 | RXRA (0.67) | RXRARXRBRXRGRARARARB | |
| SCHEMBL728017 | 1.00 | RXRA (0.67) | RXRARXRBRXRGRARARARB | |
| SCHEMBL727908 | 0.86 | RXRA (0.62) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6916140 | 0.85 | RXRA (0.61) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6833639 | 0.83 | RXRA (0.58) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6833636 | 0.83 | RXRA (0.58) | RXRARXRBRXRGRARARARB | |
| SCHEMBL727284 | 0.82 | RXRA (0.60) | RXRARXRBRXRGRARARARB | |
| SCHEMBL1140643 | 0.81 | RXRA (0.56) | RXRARXRBRXRGRARARARB | |
| SCHEMBL1140687 | 0.81 | RXRA (0.56) | RXRARXRBRXRGRARARARB | |
| SCHEMBL5175957 | 0.81 | RXRA (1.00) | RXRARXRBRXRGRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180320139-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL INC. | 2018-11-08 | — | — | US | disclosed |
| US-20160097037-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD. | 2016-04-07 | — | — | US | disclosed |
| EP-2206773-B1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD (IL) | 2012-07-11 | — | — | EP | disclosed |
| US-7955852-B2 | Expansion of renewable stem cell populations | GAMIDA CELL LTD. (IL) | 2011-06-07 | — | — | US | disclosed |
| EP-2305794-A1 | Expansion of renewable stem cell populations | Gamida Cell Ltd. (IL) | 2011-04-06 | — | — | EP | disclosed |
| US-20110033427-A1 | Expansion Of Renewable Stem Cell Populations | GAMIDA CELL LTD. (IL) | 2011-02-10 | — | — | US | disclosed |
| EP-2206773-A1 | Espansion of renewable stem cell populations | Gamida Cell Ltd. (IL) | 2010-07-14 | — | — | EP | disclosed |
| EP-1576089-B1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD (IL) | 2010-04-14 | — | — | EP | disclosed |
| EP-1576089-A4 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD (IL) | 2007-02-14 | — | — | EP | disclosed |
| EP-1601759-A4 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS USING MODULATORS OF PI 3-KINASE | GAMIDA CELL LTD (IL) | 2007-02-14 | — | — | EP | disclosed |
| WO-2004078917-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS USING MODULATORS OF PI 3-KINASE | GAMIDA-CELL LTD. (IL) | 2004-09-16 | — | — | WO | disclosed |
| US-20040049072-A1 | RXR modulators with improved pharmacologic profile | LIGAND PHARMACEUTICALS INC | 2004-03-11 | — | — | US | disclosed |
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | CANAN-KOCH STACIE (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1336600-A2 | Dimer-selective RXR modulators and methods for their use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003062369-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA-CELL LTD. (IL) | 2003-07-31 | — | — | WO | disclosed |
| US-6593493-B1 | 2-(Carboxy(unsaturated)alkyl)-1-(haloalkoxy)benzene derivatives; retinoid X receptors; cardiovascular, skin, eating and vision disorders; anticarcinogenic agents; non-insulin-dependent diabetes | LIGAND PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| US-6545049-B1 | E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof | LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-08 | — | — | US | disclosed |
| EP-1216221-A2 | RXR MODULATORS WITH IMPROVED PHARMACOLOGIC PROFILE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019770-A2 | RXR MODULATORS WITH IMPROVED PHARMACOLOGIC PROFILE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-22 | — | — | WO | disclosed |
| EP-0873295-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | RXRG, RXRB, RXRA | RXRA 3/4885RXRB 2/4885RXRG 1/4885 |
| US-20040049072-A1 | RXR modulators with improved pharmacologic profile | RXRB, RXRG, RXRA | RXRA 3/4885RXRB 1/4885RXRG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.